EUKON Legality Rating awarded
Caserta, ITALY – 03 Feb 2026 Legality Rating awarded 🚀…
Gender matter! EUKON move on mission 5
Caserta, ITALY – August 8th, 2023 We are absolutely…
IVUS + NIRS: The PROSPECT II Study Published on The Lancet
11 March 2021
The PROSPECT II Study has been published in the current issue of The Lancet.
Study findings show that combined #NIRS and #IVUS detects angiographically non-obstructive lesions with a high lipid content and large plaque burden that are at increased risk for future adverse cardiac outcomes.
Click The PROSPECT II Study to read more
Latest News:
EUKON FT1000 ranking 2022 on Financial Times
FT 1000: the sixth annual list of Europe’s fastest-growing companies…